Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23871
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hammond, Naomi E | - |
dc.contributor.author | Finfer, Simon R | - |
dc.contributor.author | Li, Qiang | - |
dc.contributor.author | Taylor, Colman | - |
dc.contributor.author | Cohen, Jeremy | - |
dc.contributor.author | Arabi, Yaseen | - |
dc.contributor.author | Bellomo, Rinaldo | - |
dc.contributor.author | Billot, Laurent | - |
dc.contributor.author | Harward, Meg | - |
dc.contributor.author | Joyce, Christopher | - |
dc.contributor.author | McArthur, Colin | - |
dc.contributor.author | Myburgh, John | - |
dc.contributor.author | Perner, Anders | - |
dc.contributor.author | Rajbhandari, Dorrilyn | - |
dc.contributor.author | Rhodes, Andrew | - |
dc.contributor.author | Thompson, Kelly | - |
dc.contributor.author | Webb, Steve | - |
dc.contributor.author | Venkatesh, Balasubramanian | - |
dc.date | 2020-07-16 | - |
dc.date.accessioned | 2020-07-27T05:09:34Z | - |
dc.date.available | 2020-07-27T05:09:34Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.citation | Intensive Care Medicine 2020; 46(9): 1696-1706 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/23871 | - |
dc.description.abstract | To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months. | en |
dc.language.iso | eng | |
dc.subject | EQ5D | en |
dc.subject | Health-related quality of life | en |
dc.subject | Intensive care | en |
dc.subject | Sepsis | en |
dc.subject | Septic shock | en |
dc.subject | Steroids | en |
dc.title | Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Intensive Care Medicine | en |
dc.identifier.affiliation | Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand | en |
dc.identifier.affiliation | Malcolm Fisher Department of Intensive Care, Royal North Shore Hospital, Sydney, Australia | en |
dc.identifier.affiliation | Royal Brisbane and Women's Hospital, Brisbane, Australia | en |
dc.identifier.affiliation | St. George's Healthcare NHS Trust, London, UK | en |
dc.identifier.affiliation | The Wesley Hospital, Brisbane, Australia | en |
dc.identifier.affiliation | The University of Queensland, Brisbane, Australia | en |
dc.identifier.affiliation | Princess Alexandra Hospital, Brisbane, Australia | en |
dc.identifier.affiliation | School of Medicine and Pharmacology, University of Western Australia, Perth, Australia | en |
dc.identifier.affiliation | Royal Perth Hospital, Perth, Australia | en |
dc.identifier.affiliation | St. George Hospital, Sydney, Australia | en |
dc.identifier.affiliation | Statistics Division, The George Institute for Global Health, UNSW Sydney, Newtown, Australia | en |
dc.identifier.affiliation | Austin Health | en |
dc.identifier.affiliation | King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.. | en |
dc.identifier.affiliation | Rigshospitalet, Copenhagen, Denmark.. | en |
dc.identifier.doi | 10.1007/s00134-020-06169-1 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-6559-7747 | en |
dc.identifier.pubmedid | 32676679 | |
dc.type.austin | Journal Article | |
local.name.researcher | Bellomo, Rinaldo | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Intensive Care | - |
crisitem.author.dept | Data Analytics Research and Evaluation (DARE) Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.